• GC
• LCO
• MAERSKa
• NOVOb
• VWS

Denmark stocks higher at close of trade; OMX Copenhagen 20 up 3.74%

Denmark's stocks rose 3.74% led by Oil & Gas, Healthcare, and Consumer Goods. Novo Nordisk, Vestas, and Maersk were top gainers; Zealand Pharma was the weakest performer.

• NOVOb
• NVO

Novo Nordisk shares rally despite setback in obesity drug trial results

Novo Nordisk's shares rose over 5% after a major market drop due to disappointing results from their obesity drug CagriSema's phase 3 trial.

• NOVOb
• NVO

Novo Nordisk shares rebound despite disappointing CagriSema trial results

Novo Nordisk's CagriSema trial showed disappointing weight loss results, leaving room for Lilly to maintain dominance in the obesity treatment market with its competing therapies.

• LLY
• NOVOb

Novo Nordisk sinks on latest data, Lilly gains

Novo Nordisk shares fell nearly 28% after CagriSema's trial results showed lower than expected weight loss, while Eli Lilly's shares rose 10% amidst the news.

• LLY
• NOVOb

Novo Nordisk shares plunge after CagriSema obesity drug trial disappoints

Novo Nordisk's obesity drug CagriSema showed a 22.7% weight loss in trials, disappointing investors and causing a significant drop in market value amid fierce competition.

• CL
• GC
• LCO
• NOVOb

Denmark stocks lower at close of trade; OMX Copenhagen 20 down 2.82%

Denmark stocks fell 2.82% with losses in Technology, Healthcare, and Real Estate sectors; falling stocks outnumbered advancers significantly.

• NOVOb

EU regulator to review potential link between Ozempic and eye condition

• NOVOb
• NVO

EU to review studies linking Novo Nordisk's Ozempic to rare eye condition

The EMA is reviewing studies linking Novo Nordisk's Ozempic diabetes drug to a rare eye condition, although no direct cause-and-effect relationship has been established yet.

• NOVOb

Denmark seeks EU review of Ozempic over vision loss concern

The Danish Medicines Agency requests a PRAC review of Ozempic due to potential links to vision loss and increased NAION risk, following new studies indicating health concerns.

• NOVOb

Novo Nordisk to invest $1.2 billion in new plant in Denmark

Novo Nordisk is investing $1.20 billion in a modular facility in Odense, Denmark for the production of drugs for rare diseases, set to be completed by 2027.